Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent 0RN4.LSE. Il ne s'agit pas d'une recommandation d'investissement.
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.